Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Feb 11:348:g366.
doi: 10.1136/bmj.g366.

Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial

Affiliations
Randomized Controlled Trial

Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial

Anthony B Miller et al. BMJ. .

Abstract

Objective: To compare breast cancer incidence and mortality up to 25 years in women aged 40-59 who did or did not undergo mammography screening.

Design: Follow-up of randomised screening trial by centre coordinators, the study's central office, and linkage to cancer registries and vital statistics databases.

Setting: 15 screening centres in six Canadian provinces,1980-85 (Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia).

Participants: 89,835 women, aged 40-59, randomly assigned to mammography (five annual mammography screens) or control (no mammography).

Interventions: Women aged 40-49 in the mammography arm and all women aged 50-59 in both arms received annual physical breast examinations. Women aged 40-49 in the control arm received a single examination followed by usual care in the community.

Main outcome measure: Deaths from breast cancer.

Results: During the five year screening period, 666 invasive breast cancers were diagnosed in the mammography arm (n=44,925 participants) and 524 in the controls (n=44,910), and of these, 180 women in the mammography arm and 171 women in the control arm died of breast cancer during the 25 year follow-up period. The overall hazard ratio for death from breast cancer diagnosed during the screening period associated with mammography was 1.05 (95% confidence interval 0.85 to 1.30). The findings for women aged 40-49 and 50-59 were almost identical. During the entire study period, 3250 women in the mammography arm and 3133 in the control arm had a diagnosis of breast cancer, and 500 and 505, respectively, died of breast cancer. Thus the cumulative mortality from breast cancer was similar between women in the mammography arm and in the control arm (hazard ratio 0.99, 95% confidence interval 0.88 to 1.12). After 15 years of follow-up a residual excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis.

Conclusion: Annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available. Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Process of randomisation and initial screening (screen 1). Breast examination was carried out by nurses unless stated otherwise (+ve indicates abnormality found by examiner, -ve no abnormality found). MA=mammography (+ve indicates abnormality found by radiologist, -ve no abnormality found). Study surgeon could order diagnostic mammography or consult with the study radiologist if necessary before sending recommendations to family doctors. Bracketed interventions indicate protocol at subsequent screens
None
Fig 2 All cause mortality, by assignment to mammography or control arms (all participants)
None
Fig 3 Breast cancer specific mortality, by assignment to mammography or control arms (all participants)
None
Fig 4 Breast cancer specific mortality from cancers diagnosed in screening period, by assignment to mammography or control arms

Comment in

References

    1. Miller AB. Conundrums in screening for cancer. Mini review. Int J Cancer 2010;126:1039-46. - PubMed
    1. Moss S. Over-diagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 2005;7:230-4. - PMC - PubMed
    1. Welch HG. Over-diagnosis and mammography screening. BMJ 2009;339:182-3. - PubMed
    1. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ 1992;147:1459-76. - PMC - PubMed
    1. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 1992;147:1477-88. - PMC - PubMed

Publication types